Aadi bioscience to present multiple posters at the american association for cancer research (aacr) annual meeting 2024

Los angeles , march 5, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor-driven cancers, today announced poster presentations at the 2024 american association for cancer research (aacr), taking place april 5-10, 2024, in san diego, ca. aacr poster presentation details are below: title: " evaluation of nab-sirolimus in combination with fulvestrant or pi3k pathway inhibitors to overcome resistance in breast cancer cell lines " session title: reversal of drug resistance 2 location: poster section 25, board number 6 abstract number: 7196 date/time: wednesday apr 10, 2024, 9:00 am - 12:30 pm presenting author: shihe hou, phd title: "correlation of nab-sirolimus tumor drug levels and improved tumor suppression in kras g12c non-small cell lung cancer xenografts treated with nab-sirolimus in combination with kras inhibitors" session title: targeting kinase and erk pathways location: poster section 46, board number 3 abstract number: 6486 date/time: tuesday apr 9, 2024 1:30 pm - 5:00 pm presenting author: shihe hou, phd more information can be found on the aacr meeting website.
AADI Ratings Summary
AADI Quant Ranking